AIM 2014 Conference

项目摘要/摘要 广泛的后天和遗传侮辱会导致共济失调，这是一种致残并经常致命的神经性疾病 无序。第五届共济失调症调查员会议“AIM 2014：迈向治疗”将汇集一个 国际调查人员名册，以解决共济失调的多学科性质，以更好地定义 研究共济失调的致病基础，探索治疗这种在很大程度上无法治愈的疾病的途径。这个 会议将集中讨论最新的科学进展和新出现的翻译方法 治疗，有以下五个目标：1)加强与共济失调有关的信息的公开交流 研究；2)促进世界各地研究人员之间的合作研究；3)提高我们的理解 人类共济失调的研究；4)为初级研究人员提供机会展示他们的工作，与 在该领域更有地位的科学家，并有机会与患者和支持团体互动，因此 他们可以看到他们工作的临床影响和重要性。AIM 2014将代表一个关键机制 促进关于共济失调研究和治疗方法的合作和讨论，这是 尤其重要的是，该领域正在进入有意义的多中心临床试验阶段 在美国和欧洲都是如此。AIM 2014会议的地点，与一年一度的 全国最大的共济失调基金会会议在同一家酒店举行，将最大限度地发挥 这次会议对科学家和患者都是一样的。 公共卫生相关性：AIM 2014将重点介绍共济失调研究和治疗的最新进展 共济失调的治疗方法。共济失调被广泛定义为运动控制的丧失，可以 影响人类运动步态、灵巧度、言语、吞咽、眼球运动和痛苦的方方面面 全球约每2000人中就有1人感染。对共济失调的新的遗传学理解最近 导致研究人员设想了共同的致病机制和可能的共同治疗方法。 这些疾病目标和治疗策略的新概念要求加强沟通和 科学家和临床医生之间的合作，以开发治疗方法，这是 目标2014年。本次会议还将为这一研究领域招募新的研究人员提供一个论坛， 是实现快速翻译成功的一个至关重要的因素。

PROJECT SUMMARY/ABSTRACT A wide range of acquired and genetic insults cause ataxia, a disabling and frequently fatal neurological disorder. The 5th Ataxia Investigators' Meeting, "AIM 2014: Advancing Toward Therapeutics," will assemble an international roster of investigators to address the multi-disciplinary nature of ataxia, to define better the pathogenic basis of ataxia, and to explore routes to therapy for what is largely an untreatable disease. The conference will focus on the most recent scientific advances and emerging translational approaches toward therapy, with the following five objectives: 1) Enhance the open exchange of information related to ataxia research; 2) Stimulate collaborative research between investigators worldwide; 3) Improve our understanding of human ataxic disorders; 4) Provide junior investigators with an opportunity to present their work, interact with more established scientists in the field, and have an opportunity to interact with patients and support groups so that they can see the clinical impact and importance of their work. AIM 2014 will represent a critical mechanism to facilitate collaboration and discussion on ataxia research and therapeutic approaches, which is of particularly great importance now that the field is entering the phase of meaningful, multi-center clinical trials both in the United States and Europe. The location of the AIM 2014 meeting, dovetailing with the annual meeting of the largest ataxia foundation in the country occurring at the same hotel, will maximize the impact of this meeting for scientists and patients alike. PUBLIC HEALTH RELEVANCE: AIM 2014 will focus on the most recent advances in ataxia research and therapeutic approaches for ataxic disorders. Ataxia, which is broadly defined as the loss of motor control, can affect all aspects of human movement gait, dexterity, speech, swallowing, and eye movements, and afflicts approximately 1 in every 2,000 individuals worldwide. Emerging genetic understanding of ataxias has recently led investigators to envision common pathogenic mechanisms and possible shared therapeutic approaches. These new concepts in disease targets and therapeutic strategy demand increased communication and collaboration among scientists and clinicians so that therapies can be developed, which is a primary goal of AIM 2014. This meeting will also provide a forum for recruiting new investigators to this field of research, which is a critically important element toward achieving rapid translational success.